Here are the latest widely reported updates on Wegovy:
Wegovy price and access: Novo Nordisk has taken steps to improve affordability for uninsured or underinsured patients, with reports noting price reductions and expanded savings programs. This reflects ongoing efforts to address payer and patient access concerns in the U.S..[2][3]
New formulations and approvals: There has been news about Wegovy-related developments, including discussions around oral GLP-1 options and additional FDA considerations that could influence how Wegovy is prescribed or substituted in practice. Such coverage often highlights regulatory milestones and market dynamics for obesity therapies.[1][8]
Market and pricing context: Coverage in major outlets has pointed to price competition and market pressure as Wegovy contends with other obesity therapies, including potential new entrants and payer-driven pricing pressures. This is part of a broader trend in diabetes/obesity drug economics shaping access and utilization.[3][9]
Related safety and expanded indications: Updates periodically address safety data, real-world use, and any expanded indications (such as related cardiovascular risk reduction studies) that may affect clinician prescribing and patient outcomes. Ongoing trial results and regulatory communications drive these narratives.[7][8]
If you’d like, I can pull the most recent, directly cited articles from specific outlets (e.g., major networks or FDA updates) and summarize them with links. I can also set up a quick digest with a timeline of Wegovy-related news over the past 3–6 months. Would you prefer a focused summary on price/access, regulatory/clinical developments, or a chronological news timeline?
Citations:
Mr. Trump announced a deal with two pharmaceutical companies to reduce the cost of popular medicines, including Wegovy and Zepbound. CBS News New York's Gwen Baumgardner has the details. Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the weight-loss drug.
www.cbsnews.comDrugmaker Novo Nordisk says it will make the popular weight GLP-1 weight loss medication Wegovy more affordable for those without insurance coverage, dropping the price to $349 a month.
abcnews.go.com/PRNewswire/ -- Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the new drug application (NDA) for Wegovy™...
www.prnewswire.comThe FDA approved a new use for a drug to reduce the risk of serious heart problems in adults with cardiovascular disease and either obesity or overweight.
www.fda.govNovo Nordisk has been swept up in uncertainty around U.S. tariffs and Washington's push to get firms to lower drug prices and move manufacturing stateside.
www.cnbc.comNews details
www.novonordisk-us.comThe maker of Ozempic is cutting the price of the drug nearly in half for some patients. Novo Nordisk had already cut the price of Wegovy, a medication with the same active ingredient that's approved for weight loss. Dr. Celine Gounder has more on the emerging price competition over the drugs. Drugmaker Eli Lilly said Thursday that things are looking good for their latest weight loss drug that would be available as a pill. Dr. Jon LaPook reports. … The budget carrier Spirit Airlines is ceasing...
www.cbsnews.comLearn about Wegovy® (semaglutide) injection 2.4 mg, 7.2 mg or tablets 25 mg for adults with obesity or overweight and see how it supports weight loss with guidance, dosing information, and savings resources to help you get started. Read important safety and prescribing info, including boxed warning.
www.wegovy.com